Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANORINAL vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LANORINAL is a combination product containing acetaminophen, which inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors via its metabolite AM404; and butalbital, a barbiturate that enhances GABA-A receptor activity, producing sedative and anxiolytic effects.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Relief of tension-type headache,Relief of muscle contraction headache
Hypertension
1-2 mg intravenously or intramuscularly every 2-4 hours as needed for pain.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in hepatic impairment.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Acetaminophen is primarily metabolized by glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3); a minor pathway via CYP2E1 produces the toxic metabolite NAPQI. Butalbital is metabolized primarily by hydroxylation via CYP2C19.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 30-50% unchanged; fecal/biliary: 50-70% as metabolites.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
99% bound, primarily to albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
0.15-0.25 L/kg, indicating limited extravascular distribution.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 70-85%.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
GFR 30-50 m L/min: administer 75% of normal dose. GFR 10-29 m L/min: administer 50% of normal dose. GFR <10 m L/min: use not recommended.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
0.02-0.05 mg/kg intravenously or intramuscularly every 4-6 hours as needed; maximum single dose 2 mg.
Not established; avoid use in children.
Initiate at 0.5-1 mg intravenously or intramuscularly; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Hepatotoxicity is often associated with use of acetaminophen in doses exceeding 4000 mg per day and often involves more than one acetaminophen-containing product.
None
Risk of hepatotoxicity with high doses or chronic use of acetaminophen; hypersensitivity reactions including anaphylaxis; risk of CNS depression and respiratory depression with butalbital; potential for abuse, dependence, and withdrawal; interactions with alcohol and other CNS depressants; use with caution in patients with hepatic or renal impairment.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to acetaminophen, butalbital, or any component; severe hepatic impairment; porphyria; history of addiction to barbiturates; concomitant use with other barbiturates or potent CNS depressants (relative).
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-fiber foods that may reduce absorption; separate by 1 hour. Limit foods high in potassium (e.g., bananas, oranges) unless advised. Avoid herbal supplements like St. John's Wort and hawthorn.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
LANORINAL (digoxin) is FDA pregnancy category C. First trimester: No well-controlled studies; animal studies show fetal toxicity at high doses. Second and third trimesters: No increased risk of major malformations with therapeutic doses; monitor for fetal bradycardia and digoxin toxicity due to increased maternal clearance. Risk of preterm labor and low birth weight from underlying maternal condition (e.g., heart failure).
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Digoxin is excreted into breast milk with a milk-to-plasma (M/P) ratio of 0.8–0.9. The relative infant dose is approximately 1–5% of the maternal weight-adjusted dose, generally considered compatible with breastfeeding. Monitor infant for bradycardia and signs of digoxin toxicity (vomiting, arrhythmias).
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Pregnancy increases digoxin clearance by 30–50%, particularly in the third trimester. Doses may need to be increased by 30–50% to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels within 2 weeks, requiring dose reduction. Monitor serum digoxin levels every 1–2 months and adjust dose accordingly.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Monitor digoxin levels closely due to narrow therapeutic index. Adjust dose in renal impairment. Check potassium and magnesium levels to avoid arrhythmias. Use with caution in elderly and patients with hypothyroidism.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not skip or double doses.,Report symptoms of toxicity: nausea, vomiting, blurred vision, irregular heartbeat.,Avoid taking with other heart medications unless directed by your doctor.,Maintain a consistent diet regarding potassium intake; avoid licorice.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANORINAL vs ALDORIL 25, answered by our medical review team.
LANORINAL is a Antihypertensive that works by LANORINAL is a combination product containing acetaminophen, which inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors via its metabolite AM404; and butalbital, a barbiturate that enhances GABA-A receptor activity, producing sedative and anxiolytic effects.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANORINAL and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANORINAL is: 1-2 mg intravenously or intramuscularly every 2-4 hours as needed for pain.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANORINAL and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANORINAL is classified as Category C. LANORINAL (digoxin) is FDA pregnancy category C. First trimester: No well-controlled studies; animal studies show fetal toxicity at high doses. Second and third trimesters: No incr. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.